Table 2.
Changes in the serum sclerostin levels in osteoporosis.
| Authors,Year | Type of Study | Study Subjects | Major Findings |
|---|---|---|---|
| Cosman et al., 2016 (84) | A Randomized controlled clinical trial | 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck | Anti-sclerostin antibody therapy can increase bone formation and increase BMD, thereby reducing the risk of fracture |
| McClung et al., 2014 (85) | A Phase II, multicenter, international, randomized, placebo-controlled, parallelgroup, eight-group study | 419 postmenopausal women | Anti-sclerostin antibody therapy can significantly improve BMD at the lumbar spine |
| Poutoglidou et al., 2022 (86) | A Meta-Analysis and Systematic Review | – | At 6 and 12 months, anti-sclerostin antibody significantly increase BMD in the lumbar spine, total hip and femoral neck |
| Lewiecki et al., 2018 (88) | A Phase III Randomized Placebo-Controlled Trial | 245 subjects (163 romosozumab, 82 placebo) | Anti-sclerostin antibody therapy can improve BMD in male patients with osteoporosis |
| Recker et al., 2015 (89) | A Randomized, Double‐Blind Phase 2 Clinical Trial | 120 postmenopausal women between 45 and 85 years of age, with a lumbar spine BMD T‐score of –2.0 to –3.5, inclusive | Anti-sclerostin antibody treatment can significantly increase BMD in the spine, femoral neck, and total hip as compared with placebo, which is dose-dependent |
| Kaveh et al., 2020 (90) | A Systematic review and Meta-analysis | – | Treatment with anti-sclerostin antibody can be a proper therapeutic option in patients with osteoporosis and low BMD |
| Lee et al., 2022 (91) | A case report | a 67-year-old woman with nonunion of humerus shaft fracture | Anti-sclerostin antibody therapy can aid in promoting bone healing of nonunion |